Radiotheranostics: a roadmap for future development
Ken Herrmann, Markus Schwaiger, Jason Stuart Lewis et al. · The Lancet Oncology · 2020
Cited by 327 works. doi:10.1016/s1470-2045(19)30821-6
Authors
- Ken Herrmann
- Markus Schwaiger
- Jason Stuart Lewis
- Stephen Barnett Solomon
- Barbara Joyce McNeil
- Michael A. Baumann
- Sanjiv Sam Gambhir
- Hedvig Hricak
- Ralph Weissleder
References
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
- Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
- [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
- Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
- Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience
- Prostate Cancer, Version 1.2016
- Guidelines for radioiodine therapy of differentiated thyroid cancer
- RADIOACTIVE IODINE THERAPY